Aisai is rolling out its anti-epileptic drug, Fycompa (perampanel), across Europe with a determination to reach pricing agreements rather than risk unfavorable negotiations at higher prices, said Gary Hendler, EMEA president and CEO.
Follow-up data requirements and physicians’ readiness to use the drug may delay the company reaching its sales target of making USD 1bn in the first three years, experts noted.
The European Medicines Agency (EMA) approved Fycompa, an AMPA receptor antagonist, as an adjunctive treatment of partial-onset seizures, with or without secondarily generalized seizures, in people with epilepsy aged 12 years and older.
The drug is currently available in the UK at GBP 5 per day (about $8 USD) across all five available doses, Hendler said. The defined daily dose (DDD) has not yet been established, he added.
This drug offers huge promise and we will keep you posted with news on it’s effectiveness and the availability in the United States.